Should radiotherapy be
omitted in some early breast
cancer patients?
Yong Bae Kim MD
Dept. of Radiation Oncology, Yonsei Cancer Center
Introduction
Breast-conserving surgery (BCS) followed by
radiation therapy (RT)
Standard treatment for the majority of women with
early-stage invasive breast cancer
50.4 Gy/ 28 fractions to whole breast
10 Gy/ 5 fractions to tumor bed
Reasons to avoid RT
Inconvenience
RT schedule of 6~6.5 weeks (30~33 fractions)
Radiation toxicity
Breast swelling, muscle pain, breast discomfort, fibrosis Radiation pneumonitis
Cardiac toxicity
Secondary malignancies
RT in low risk early breast cancer
N F/U (yrs) Age >50 (%) ER/PR + (%) TAM/AI (%) G 1-2 (%) IBTR (%) RT No RT NSABP B21 1009 8 80 56.5 67 67 9.3 2.8 16.5 PMH 769 5.6 100 80.5 100 68.3 0.6 7.7 ABSCG Study 8a 869 4.48 99 100 100 95 0.4 5.1 CALGB 9343 626 10.5 100 97 100 - 2 8 GBSG-V 347 9.9 91.4 88 50 97.2 6 20 BASO II 1172 4.5 - - 25 100 1.3 3.6 PRIME 255 5 100 - - 94.5 0 6RT in low risk early breast cancer
Small absolute local recurrence risk reduction
→ small mortality benefit
⇒
Should we omit RT?
However, it is clear that RT is effective on reducing
local recurrence, even though RT may not affects
survival in these patients.
Accelerated whole breast irradiation (AWBI)
Accelerated whole breast irradiation (AWBI)
These studies demonstrate that hypofractionation (HF)
yields equivalent or improved outcomes in all essential end
point parameters: efficacy, toxicity, cosmesis, and
cost-effectiveness.
HF-WBI also results in greater patient convenience and
resource efficiency.
Accelerated Partial breast irradiation (APBI)
External beam radiation therapy
(EBRT)
Brachytherapy
Multicatheter interstitial
brachytherapy
Intracavitary brachytherapy
Intraoperative radiation therapy
(IORT)
Accelerated Partial breast irradiation (APBI)
Reasons to avoid RT
Inconvenience
RT schedule of 6.5 weeks (33 fractions)
Radiation toxicity
Breast swelling, muscle pain, breast discomfort, fibrosis Radiation pneumonitis
Cardiac toxicity
Secondary malignancies
RT induced cardiac toxicity
Population-based case-control study of major
coronary events
Sweden and Denmark, 1958-2001, age <70 or 75 years n=2168: 963 case, 1205 controls
Major coronary events: myocardial infarction, coronary
revascularization, death from ischemic heart disease (IHD)
Dose-volume histogram for the whole heart and for the left
anterior descending coronary artery
RT induced cardiac toxicity
Risk factors
Lt. breast (RR 1.32, p=0.002), LN (+) (p=0.06)
History of IHD (RR 6.67, p<0.001)
History of other circulatory disease, DM, COPD,
current smoker, high BMI, regular analgesic use,
hormone-replacement
RT induced cardiac toxicity
Effect of RT
Mean doses to heart: 4.9 Gy (overall), 6.6 Gy (Lt), 2.9 Gy (Rt)
↑7.4 % / Gy (95% CI 2.9-14.5) p<0.001 ↑8.4 % / Gy (95% CI 3.6-15.9) p<0.001 Average (Gy)
Correlation with mean dose to whole heart
Cases
Whole heart 5.4 -
Lt. ant descending coronary a. 9.9 -
Whole heart (EQD2 Gy) 4.4 -
Controls
Whole heart 4.5 -
Lt. ant descending coronary a. 9.0 -
Whole heart (EQD2 Gy) 3.5 -
All
Whole heart 4.9 -
Lt. ant descending coronary a. 9.4 0.76 Whole heart (EQD2 Gy) 3.9 0.98
P<0.001 P=0.001
Reducing cardiac dose
Deep inspirational breathing hold (DIBH) technique
The maximum separation between the target area and heart
can be achieved only at or near maximum inspiration
Respiration control
Active breathing control (ABC) device, Real-time Position
Management (RPM) system, Self respiration monitoring (SRM) system, Abches etc.
Intensity modulated RT (IMRT)
Prone positioning
DIBH using Abches
Left-sided breast cancer, n=25
Respiratory control using Abches system
Free breathing (FP) vs. DIBH
DIBH using Abches
FB plan DIBH plan P
Heart
Mean dose (Gy) 4.53 2.52 <0.001
V30 (%) 6.31 2.80 <0.001
V30 absolute volume (cm3) 45.13 16.48 <0.001
V20 (%) 7.64 3.16 <0.001
V20 absolute volume (cm3) 54.55 21.35 <0.001
LAD Mean dose (Gy) 26.26 16.01 <0.001
Dmax 0.2cm3 47.27 41.65 0.017
Lung
Mean dose (Gy) 8.04 7.53 0.073
V20 (%) 15.72 14.63 0.060
IMRT
Left-sided breast cancer, n=12
3D CRT vs. IMRT
Radiather Oncol (2013) 248-253
3D CRT with BH IMRT with BH
IMRT
3D CRT plan IMRT plan P
Heart
Mean dose (Gy) 1.8 1.5 <0.01
Dmax (Gy) 15.8 8.6 <0.01
V30 (%) 1.0 0.2 <0.01
V20 (%) 1.5 0.6 <0.01
LAD
Mean dose (Gy) 9.6 6.7 <0.01
Dmax (Gy) 25.2 18.8 <0.01
V20 (%) 17.8 9.7 <0.01
Lung
Mean dose (Gy) 3.0 2.6 <0.01
V20 (%) 6.2 5.1 <0.01
Prone positioning
Approximate cardiac doses associated with various
selected techniques
The absolute benefits of radiation are likely to be increased with modern techniques. Most studies of patients treated with modern techniques do not report
cardiotoxicity.
Nevertheless, the effects seen at low doses in the study by Darby et al. highlight the
need for continued diligence.
Reasons to avoid RT
Inconvenience
RT schedule of 6.5 weeks (33 fractions)
Radiation toxicity
Breast swelling, muscle pain, breast discomfort, fibrosis Radiation pneumonitis
Cardiac toxicity
Secondary malignancies
3. Secondary malignancies after breast RT
EBCTCG meta-analysis
Incidence of contralateral breast cancer: RR 1.18 (p=0.002) Incidence of other specified cancer: RR 1.20 (p=0.001)
Lung (RR 1.61, p=0.0007), esophagus (RR 2.06, p=0.05),
leukemia (RR 1.71, p=0.04), soft tissue sarcoma (RR 2.34, p=0.03)
Mortality by other cause; heart disease etc.
3. Secondary malignancies after breast RT
SEER database
1973-2002, 15 cancer that are routinely treated with RT
Breast cancer: RT (n=90,613, 40%) vs. no RT (n=137,191, 60%)
RR of second solid cancer
Overall: 1.1 (95% CI 1.07-1.13)
Low (<1 Gy), medium (1-5 Gy), high (>5 Gy): p-trend <0.0001 Attributable risk: 5% (95% CI 4-7)
Lancet Oncol 2011; 12; 353-60
A relatively small proportion of second cancers are related
to radiotherapy in adults, suggesting that most are due to
other factors, such as lifestyle or genetics.
Summary
Some physicians suggest the omission of RT in patients with
low risk early breast cancer.
However, new RT modality can be applied to achieve maximal
local control and pt’s safety and convenience in early breast cancer
Modification of RT fractionation (HF-WBI, PBI) ⇒ increase convenience of patients
Decreased cardiac toxicity through reducing cardiac dose using DIBH, prone position or IMRT
Only small proportion of secondary malignancy after RT was related with RT.